# CJC-1295 Ipamorelin Dosage in the Research Literature

> CJC-1295 ipamorelin dosage protocols from preclinical and Phase I/II-context human studies: dose ranges by species, routes, half-life data, timing considerations, and reconstitution notes.

All dose parameters on this page are derived from preclinical and published Phase I/II-context research data. They are research-context parameters, not clinical guidance for human use. Neither CJC-1295 nor ipamorelin is FDA-approved.

## Dose Ranges Studied in Preclinical and Human Protocols

**CJC-1295 (with DAC) in human studies:** Ionescu and Frohman (2006) studied doses of 60 µg/kg and 90 µg/kg via subcutaneous injection in healthy men, producing 46% mean GH elevation and 45% IGF-1 elevation at one week.[1]

**CJC-1295 in rodent studies:** Alba et al. (2006) administered 2 µg/day to GHRH-knockout mice, normalizing body weight, length, lean mass, and subcutaneous fat mass.[5]

**Ipamorelin in rat studies:**
- Johansen et al. (1999): dose-dependent series, subcutaneous, 15-day bone-growth protocols.[4]
- Andersen et al. (2001): 100 µg/kg three times daily SC for glucocorticoid-counteraction studies.[8]
- Svensson et al. (2000): 0.5 mg/kg/day for 12-week bone mineral content studies.[9]
- Venkova et al. (2009): 0.01–1 mg/kg IV four times daily for GI motility restoration.[10]

## CJC-1295 and Ipamorelin Half-Life

CJC-1295 without DAC: below 10–13 minutes due to rapid DPP-IV N-terminal cleavage.[16] CJC-1295 with DAC: approximately 6–8 days in humans, confirmed by sustained IGF-1 elevation persisting beyond 14 days from a single dose[1] and plasma detection beyond 72 hours post-SC-dose in rats.[2]

Ipamorelin: approximately 2 hours in rodents, based on 5-fold lower plasma clearance than GHRP-6 and 60–80% of dose recoverable as intact peptide from bile and urine.[7] No formally published human pharmacokinetic data exist.

## Injection Frequency in Study Protocols

CJC-1295 with DAC: once-weekly or less frequent subcutaneous injection in human Phase I/II-context studies.[1] Ipamorelin in animal models: 1–3 daily doses.[8][10] Human combination injection frequency protocols have not been published.

## Fasting State and Injection Timing

Research protocols typically specify fasted-state administration. In a 5-day fast study in men, GH pulse frequency increased from 5.8 to 9.9 pulses per 24 hours (p=0.028) and 24-hour GH concentration rose from 2.82 to 8.75 µg·min/mL (p=0.0002), with somatostatin suppression identified as the primary mechanism.[11] Ghrelin administration enhanced slow-wave sleep and delta-wave activity in human subjects,[12] providing mechanistic basis for pre-sleep injection timing in GHS research protocols.

## Time Course of Effects

CJC-1295 produced sustained GH elevations within hours in human Phase I/II-context trials; IGF-1 elevation confirmed at one week post-dose.[1] Body composition and bone endpoints in animal studies showed measurable changes at 4–12 weeks.[4][8][9]

## Reconstitution and Handling

Lyophilized peptide vials are reconstituted with bacteriostatic water (0.9% benzyl alcohol) in research settings. Standard protocols add BAC water slowly down the vial wall — not directly onto the lyophilized pellet — to avoid agitation-induced aggregation. Reconstituted solutions degrade via asparagine deamidation; degradation products may be 25–500-fold less potent than intact peptide. Store reconstituted solutions at 2–8°C.

## References

[1] Ionescu M, Frohman LA. J Clin Endocrinol Metab. 2006;91(12):4792-4797. https://pubmed.ncbi.nlm.nih.gov/17018654/
[2] Jetté L, et al. Endocrinology. 2005;146(7):3052-3058. https://pubmed.ncbi.nlm.nih.gov/15817669/
[4] Johansen PB, et al. Growth Horm IGF Res. 1999;9(2):106-113. https://pubmed.ncbi.nlm.nih.gov/10373343/
[5] Alba M, et al. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. https://pubmed.ncbi.nlm.nih.gov/16822960/
[7] Johansen PB, et al. Xenobiotica. 1998;28(12):1243-1252. https://pubmed.ncbi.nlm.nih.gov/9879640/
[8] Andersen NB, et al. Growth Horm IGF Res. 2001;11(5):266-272. https://pubmed.ncbi.nlm.nih.gov/11735244/
[9] Svensson J, et al. J Endocrinol. 2000;165(3):569-577. https://pubmed.ncbi.nlm.nih.gov/10828840/
[10] Venkova K, et al. J Pharmacol Exp Ther. 2009;329(3):1110-1116. https://pubmed.ncbi.nlm.nih.gov/19289567/
[11] Ho KY, et al. J Clin Invest. 1988;81(4):968-975. https://pubmed.ncbi.nlm.nih.gov/3127426/
[12] Weikel JC, et al. Am J Physiol Endocrinol Metab. 2003;284(2):E407-E415. https://pubmed.ncbi.nlm.nih.gov/12388174/
[16] Memdouh S, et al. Drug Test Anal. 2021;13(7):1233-1247. https://pubmed.ncbi.nlm.nih.gov/34665524/

---

Twenty-two studies across six species, indexed as a folk-almanac of the CJC-1295 ipamorelin literature — no clinic behind the cordel, no vendor behind the broadside.